Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

NCT07691450 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07691450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 3, 2027
Completion date
November 24, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic large cell lymphoma, recurrent enteropathy-associated t-cell lymphoma, recurrent follicular helper t-cell lymphoma, recurrent follicular helper t-cell lymphoma, angioimmunoblastic-type, recurrent follicular helper t-cell lymphoma, follicular-type, recurrent follicular helper t-cell lymphoma, not otherwise specified, recurrent hepatosplenic t-cell lymphoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent monomorphic epitheliotropic intestinal t-cell lymphoma, recurrent peripheral t-cell lymphoma, not otherwise specified, recurrent primary cutaneous cd8-positive aggressive epidermotropic cytotoxic t-cell lymphoma, recurrent primary cutaneous gamma-delta t-cell lymphoma, recurrent subcutaneous panniculitis-like t-cell lymphoma, refractory anaplastic large cell lymphoma, refractory enteropathy-associated t-cell lymphoma, refractory follicular helper t-cell lymphoma, refractory follicular helper t-cell lymphoma, angioimmunoblastic-type, refractory follicular helper t-cell lymphoma, follicular-type, refractory follicular helper t-cell lymphoma, not otherwise specified, refractory hepatosplenic t-cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory monomorphic epitheliotropic intestinal t-cell lymphoma, refractory peripheral t-cell lymphoma, not otherwise specified, refractory primary cutaneous cd8-positive aggressive epidermotropic cytotoxic t-cell lymphoma, refractory primary cutaneous gamma-delta t-cell lymphoma, refractory subcutaneous panniculitis-like t-cell lymphoma